SIGA Technologies, Inc. (SIGA)
NASDAQ: SIGA · Real-Time Price · USD
5.02
+0.02 (0.40%)
Mar 25, 2026, 2:07 PM EDT - Market open
Company Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States.
The company’s lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
SIGA Technologies, Inc.
| Country | United States |
| Founded | 1995 |
| IPO Date | Sep 9, 1997 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Diem Nguyen |
Contact Details
Address: 31 East 62nd Street New York, New York 10065 United States | |
| Phone | 212 672 9100 |
| Website | siga.com |
Stock Details
| Ticker Symbol | SIGA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001010086 |
| CUSIP Number | 826917106 |
| ISIN Number | US8269171067 |
| Employer ID | 13-3864870 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Diem Nguyen M.B.A., Ph.D. | Chief Executive Officer and Director |
| Daniel J. Luckshire CPA, M.B.A. | Executive Vice President, Chief Financial Officer and Secretary |
| Dr. Dennis E. Hruby Ph.D. | Executive Vice President and Chief Scientific Officer |
| Lawrence R. Miller Esq., J.D. | General Counsel and Corporate Secretary |
| Herb Vloedman | Senior Vice President and Chief Information Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 10, 2026 | 10-K | Annual Report |
| Mar 10, 2026 | 8-K | Current Report |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |
| Aug 5, 2025 | 10-Q | Quarterly Report |
| Aug 5, 2025 | 8-K | Current Report |
| Jun 12, 2025 | 8-K | Current Report |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 28, 2025 | ARS | Filing |